These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1915505)

  • 21. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
    Markham A; Bryson HM
    Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nursing care of predialysis patients receiving epoetin alfa.
    Brown JM
    ANNA J; 1991 Jun; 18(3):306-14. PubMed ID: 2064456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
    Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P
    Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 27. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 29. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 30. Erythropoietin: a therapeutic tool.
    Agarwal MB
    J Assoc Physicians India; 1992 Jan; 40(1):9-10. PubMed ID: 1634473
    [No Abstract]   [Full Text] [Related]  

  • 31. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics of anaemia treatment in children with chronic kidney disease].
    Puretić Z
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():27-32. PubMed ID: 20235352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis. Secondary effects of the increase of haemoglobin.
    Zehnder C; Glück Z; Descoeudres C; Uehlinger DE; Blumberg A
    Nephrol Dial Transplant; 1988; 3(5):657-60. PubMed ID: 3146724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients].
    Jacquot C; Berthelot JM; Chiappini-Judith D; Ferragu-Haguet M; Lefebvre A; Masselot JP; Moynot A; Frydman MO; Peterlongo F
    Nephrologie; 1990; 11(1):11-6. PubMed ID: 2374641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.
    Vanrenterghem Y; Vanwalleghem J
    Nephrol Dial Transplant; 1998; 13 Suppl 2():13-5. PubMed ID: 9566485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 40. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.